8-K: Haemonetics Prices $600 Million Convertible Senior Notes Offering, Repurchases 2026 Notes

Haemonetics has priced a $600 million convertible senior notes offering and will repurchase $200 million of its 2026 notes.

Summary

• Haemonetics Corporation has announced the pricing of a $600 million private offering of 2.50% convertible senior notes due in 2029.
• The offering size was increased from the previously announced $525 million.
• The company also granted the initial purchasers an option to buy an additional $100 million in notes.
• The notes will mature on June 1, 2029, and can be converted into Haemonetics common stock starting December 1, 2028.
• The initial conversion rate is 8.5385 shares per $1,000 principal amount, equivalent to a conversion price of approximately $117.12 per share.
• This conversion price represents a 30% premium over the closing price of $90.09 on May 22, 2024.
• Haemonetics estimates net proceeds of approximately $584.8 million, or $682.3 million if the option is fully exercised.
• The company intends to use the proceeds to pay for capped call transactions, repurchase $200 million of 2026 notes, repay $230 million on its revolving credit facility, and for general corporate purposes.
• Concurrently, Haemonetics will repurchase $200 million of its 2026 convertible senior notes for $185.5 million in cash.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the successful upsized offering and strategic debt management. However, the potential for dilution and the cost of the capped call transactions temper the overall positive outlook.

Positives

• The upsized offering indicates strong investor demand for Haemonetics' debt.
• The repurchase of the 2026 notes reduces near-term debt obligations.
• The capped call transactions are expected to reduce potential dilution from the convertible notes.
• The company is using the proceeds to strengthen its balance sheet by repaying its revolving credit facility.
• The conversion price of $117.12 represents a premium over the current share price.

Negatives

• The company is taking on additional debt with the new convertible notes.
• The conversion of the notes could potentially dilute existing shareholders.
• The company is paying a premium to repurchase the 2026 notes.
• The capped call transactions have a cap price of $180.18, which if exceeded, could result in dilution and/or cash payments.

Risks

• The offering may not close as expected due to market conditions or other factors.
• Fluctuations in the trading price of Haemonetics common stock could impact the conversion value of the notes.
• The capped call transactions may not fully offset the potential dilution from the convertible notes.
• The company may not be able to repurchase the remaining 2026 notes on favorable terms.
• General economic, industry, or political conditions could impact the company's performance.

Future Outlook

Haemonetics expects to use the net proceeds from the offering to pay for capped call transactions, repurchase 2026 notes, repay its revolving credit facility, and for general corporate purposes, including potential additional repurchases of the 2026 notes.

Management Comments

• Haemonetics announced the pricing of its offering of $600 million aggregate principal amount of 2.50% Convertible Senior Notes due 2029.
• Haemonetics expects to use the net proceeds from the offering to pay for capped call transactions, repurchase 2026 notes, repay its revolving credit facility, and for general corporate purposes.

Industry Context

This announcement is part of a broader trend of companies using convertible debt to raise capital, particularly in the healthcare sector. The concurrent repurchase of existing debt is a common strategy to manage liabilities and reduce interest expenses.

Comparison to Industry Standards

• The 2.50% interest rate on the convertible notes is within the typical range for similar offerings by companies with comparable credit ratings.
• The 30% premium on the conversion price is a common feature in convertible note offerings, designed to attract investors while minimizing immediate dilution.
• The use of capped call transactions to mitigate dilution is a standard practice in convertible debt issuances.
• Other companies in the medical device industry, such as Medtronic and Stryker, have also utilized convertible debt to fund acquisitions and capital expenditures.

Stakeholder Impact

• Shareholders may experience potential dilution if the notes are converted.
• Creditors will see a reduction in the company's revolving credit facility balance.
• Noteholders will receive interest payments and have the option to convert their notes into common stock.
• The company's financial position is expected to improve with the debt restructuring.

Next Steps

• The offering is expected to close on May 28, 2024.
• Haemonetics will use the proceeds as outlined in the press release.
• The company may repurchase additional 2026 notes in the future.

Key Dates

Keywords

convertible notes, debt offering, capital raise, share repurchase, capped call, senior notes, Haemonetics, financing, dilution, revolving credit facility